REG - Tristel PLC - Holding(s) in Company

TristelAnnouncement

Mon 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260420:nRST1754Ba&default-theme=true

RNS Number : 1754B  Tristel PLC  20 April 2026

 

Tristel plc

("Tristel" or the "Company")

 

Holding(s) in Company

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces that it was notified on 17 April 2026 that, as of 16 April
2026, Artemis Investment Management LLP, holds, 3.00216 per cent. of the
Company's issued share capital.

 

For further information please contact:

 

 Tristel plc                                                                   Via Walbrook PR
 Matt Sassone, Chief Executive Officer                                         www.investors.tristel.com (http://www.investors.tristel.com/)
 Anna Wasyl, Chief Financial Officer

 Walbrook PR Ltd             Tel: 020 7933 8780 or tristel@walbrookpr.com
                             (mailto:tristel@walbrookpr.com?subject=tristel@walbrookpr.com)
 Paul McManus / Lianne Applegarth / Anna Dunphy          Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

 Cavendish Capital Markets Ltd                                                 Tel: 020 7220 0500
 Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)
 Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

About Tristel plc

 

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO2) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals with products under
the Tristel brand, which also encompasses its sporicidal surface disinfection
range offered as a sustainable alternative to commonly used pre‑wetted
plastic wipe.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets delivering
double-digit revenue growth annually, an adjusted EBITDA margin of at least
25% and a continuing progressive year-on-year growth in dividends, underpinned
by robust cash generation.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLAKKBBNBKDQQB



            Copyright 2019 Regulatory News Service, all rights reserved